This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Sign In   |   Register
News: FHSC

FH Week: Putting FH on the public agenda - EAS clinicians go-to resouce for FH

Friday 22 September 2017   (0 Comments)
Share |

Putting FH on the public health agenda –
EAS clinicians go-to resource for FH

September 24 is FH-awareness day All this week, in a series of newsletters, EAS has highlighted activities that are putting FH on the public health agenda.We have gathered the key points from this weeks newsletters comprising publications, education and a list of national FH events from all over the world.

Why is action on FH needed?

FH – a common hereditary cause of premature cardiovascular disease

The hallmark of Familial Hypercholesterolaemia (FH) is high LDL-cholesterol. The disease is carried by one in 200–300 persons in the heterozygous form — that is to say, about 2 million people in Europe carry FH. It is present from early childhood, but without noticeable symptoms until the third or fourth decade in life, when heart disease will appear. If untreated, 50% of men with FH suffer a heart attack before they are 50 years old, and women before they reach the age of 55. FH is a ticking bomb that, if untreated, will cause cardiovascular disease or death.

FH is underdiagnosed

When detected, FH can be treated, but there are few countries in Europe where is FH systematically sought and diagnosed. As FH runs in families — a child of a parent with FH has a 50% chance of inheriting the disorder — when one person is diagnosed, a systematic search of their relatives will identify other family members carrying FH. The tool to detect the patients is available and is easily applicable to everyday clinical practice.

FH can be treated

Treatment with statins will bring many patients’ cholesterol levels down to “normal”. If diagnosed early, treatment can give persons with FH a normal life expectancy. Even when FH is diagnosed later in life, treatment will dramatically improve life expectancy. Yet, in most European countries less than 10% of FH patients are treated.

EAS-FHSC – a global registry towards a better understanding of FH

The European Atherosclerosis Society FH Studies Collaboration (EAS-FHSC) is a consortium of international stakeholders working together to establish a global FH registry. Its purpose is to generate large-scale, robust data on the burden of FH worldwide, and establish the true public health impact of FH.

The EAS-FHSC network keeps growing, counting to date over 65 countries worldwide, and constitutes the first global initiative that, through joint international efforts, is working towards a better understanding of FH to ultimately inform and impact the guidelines on FH management.

The recently launched HoFH International Clinical Collaboration (HICC) registry aims to create a formal international network of healthcare providers who manage HoFH patients that transcends the regional nature of current efforts.

Read more about FH Studies Collaboration and the registry >>

Read more about the HoFH International Clinical Collaboration - HICC >>

EAS educating clinicians about FH

EAS Educational platform EAS Academy is introducing you to the Basics of Familial Hypercholesterolaemia. The online educational platform is a major source of information about atherosclerosis, lipid disorders, cardiovascular prevention and basic science in the field of atherosclerosis and metabolism.


The accredited online learning programme on FH, available on EAS Academy, gives a broad overview of the genetic dyslipidaemia, Familial Hypercholesterolaemia (FH), with insight into the genetics of the disease, the basic molecular mechanisms, and its clinical development


Read more about FH on the EAS Academy >>

To the Introduction in Familial Hypercholesterolaemia FH >>

To the EAS Certificate of Education in FH >>

Publications, resources & tools on FH for clinicians

EAS and the FH Studies Collaboration are working on raising awareness of FH in the medical community through publications and online resources like Guidelines & Consensus publications, Advanced Courses, Congress symposia, and online learning through EAS Academy and other resources.

Find out more about the publications, resources and tools >>


Events in Europe and worldwide

Around the world this week, groups including atherosclerosis societies and FH patient organisations are holding events and organising activities to raise awareness of FH among the general public and healthcare professionals. The more people are aware of FH, the more likely we are to get FH onto the public health agenda.

List of National FH Events 2017 >>
About FH Week and EAS activities on FH >>

Membership Software Powered by YourMembership  ::  Legal